INS and type 1 diabetes mellitus: A phase 2 clinical study by the same group using the L-type calcium channel blocker verapamil showed improved beta cell function, lowered insulin requirements, fewer hypoglycemic events, and on-target glycemic control in patients with T1DM [140].